Edition:
United States

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

376.80GBp
17 Nov 2017
Change (% chg)

-- (--)
Prev Close
376.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,026,785
52-wk High
421.50
52-wk Low
246.50

Chart for

About

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue... (more)

Overall

Beta: --
Market Cap(Mil.): £2,714.74
Shares Outstanding(Mil.): 721.46
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

UK's Indivior posts profit in third quarter as costs fall

British drugmaker Indivior on Thursday reported a quarterly profit compared with a year-ago loss, as it benefited from lower costs.

Nov 02 2017

UPDATE 1-UK's Indivior posts profit in 3rd quarter as costs fall

Nov 2 British drugmaker Indivior on Thursday reported a quarterly profit compared with a year-ago loss, as it benefited from lower costs.

Nov 02 2017

UK's Indivior posts profit compared with year-ago loss

Nov 2 British drugmaker Indivior posted a quarterly profit compared with a year-ago loss, helped by strength in its U.S. business and lower costs.

Nov 02 2017

BRIEF-Indivior says Q3 net revenue $‍275​ mln vs. $268 mln

* Q3 NET REVENUE $‍275​ MILLION VERSUS $268 MILLION A YEAR AGO

Nov 02 2017

Indivior drug to fight opioid addiction recommended by U.S. panel

Indivior's experimental drug to help fight America's growing opioid addiction crisis has been recommended for approval by a U.S. advisory panel, boosting its sales prospects as competitors threaten revenues from an older product.

Nov 01 2017

UPDATE 3-Indivior drug to fight opioid addiction recommended by U.S. panel

* Indivior shares jump 11 percent (Adds further sales forecasts, latest share price, details)

Nov 01 2017

BRIEF-FDA committees recommend approval of Indivior's RBP-6000 for the treatment of opioid use disorder

* FDA advisory committees recommend approval of Indivior's RBP-6000 for the treatment of opioid use disorder

Oct 31 2017

U.S. FDA panel backs approval for Indivior opioid addiction drug

Oct 31 Indivior Plc's experimental drug to treat opioid addiction should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday.

Oct 31 2017

Reckitt Benckiser unit beats states' Suboxone antitrust claims

A U.S. judge on Tuesday dismissed a unit of Reckitt Benckiser Group plc from a lawsuit by state attorneys general accusing it and spin-off Indivior Plc of scheming to block generic competition of the opioid addiction treatment drug Suboxone.

Oct 17 2017

BRIEF-Old Mutual cuts stake in Indivior to 4.36 pct

* OLD MUTUAL CUTS STAKE IN INDIVIOR TO 4.36 PERCENT FROM 7.01 PERCENT STAKE EARLIER- FILING‍​ Further company coverage:

Oct 09 2017

Earnings vs. Estimates